Annals of Surgical Oncology

, Volume 24, Issue 5, pp 1419–1427 | Cite as

Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I–II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base

  • Todd A. Pezzi
  • Abdallah S. R. Mohamed
  • Clifton D. Fuller
  • Pierre Blanchard
  • Christopher Pezzi
  • Boris Sepesi
  • Stephen M. Hahn
  • Daniel R. Gomez
  • Stephen G. Chun
Radiation Oncology
  • 326 Downloads

Abstract

Background

The 1998 post-operative radiotherapy meta-analysis for lung cancer showed a survival detriment associated with radiation for stage I–II resected non-small cell lung cancer (NSCLC), but has been criticized for including antiquated radiation techniques. We analyzed the National Cancer Database (NCDB) to determine the impact of radiation after margin-negative (R0) resection for stage I–II NSCLC on survival.

Methods

Adult patients from 2004 to 2014 were analyzed from the NCDB with respect to receiving radiation as part of their first course of treatment for resected stage I–II NSCLC; the primary outcome measure was overall survival.

Results

A total of 197,969 patients underwent R0 resection for stage I–II NSCLC, and 4613 received radiation. Median radiation dose was 55 Gy with a 50–60 Gy interquartile range. On adjusted analysis, treatment at a community cancer program, sublobectomy, tumor size (3–7 cm), and pN1/Nx were associated with receiving radiation (odds ratio > 1, p < 0.05). The irradiated group had shorter median survival (45.8 vs. 77.5 months, p < 0.001), and radiation was independently associated with worse overall survival (hazard ratio (HR) 1.339, 95% confidence interval (CI) 1.282–1.399). After propensity score matching, radiation remained associated with worse overall survival (HR 1.313, 95% CI 1.237–1.394, p < 0.001).

Conclusions

Radiotherapy was independently associated with worse survival after R0 resection of stage I–II NSCLC in the NCDB and was more likely to be delivered in community cancer programs.

Keywords

Overall Survival Propensity Score Match Supplemental Appendix National Cancer Data Base Irradiate Group 

Notes

Acknowledgment

We are appreciative of discussion with Ying Yuan, PhD, Department of Biostatistics, MD Anderson Cancer Center. Drs. Mohamed and Fuller received funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (1R01DE025248-01/R56DE025248-01) and the NIH/National Cancer Institute (NCI) Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program award (P50CA097007-10). Dr. Fuller received support from the Paul Calabresi Clinical Oncology Program Award (K12 CA088084-06); a National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD), Grant (NSF 1557679); an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; and the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center. Dr. Fuller has received speaker travel funding from Elekta AB. Supported in part by the NIH/NCI Cancer Center Support (Core) Grant CA016672 to the University of Texas MD Anderson Cancer Center.

Disclosure

The authors declare that they have no conflict of interest to report.

Supplementary material

10434_2017_5786_MOESM1_ESM.docx (96 kb)
Supplementary material 1 (DOCX 96 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14:255–64.PubMedGoogle Scholar
  3. 3.
    Wang X, Yan S, Phan K, et al. Mediastinal lymphadenectomy fulfilling NCCN criteria may improve the outcome of clinical N0–1 and pathological N2 non–small cell lung cancer. J Thorac Dis. 2016;8:342–49.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hofmann HS, Taege C, Lautenschlager C, Neef H, Silber RE. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non–small cell lung cancer. Eur J Cardiothorac Surg. 2002;21:606–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Snijder RJ, Brutel de la Riviere A, Elbers HJ, van den Bosch JM. Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin. Ann Thorac Surg. 1998;65:212–16.Google Scholar
  6. 6.
    Ghiribelli C, Voltolini L, Paladini P, Luzzi L, Di Bisceglie M, Gotti G. Treatment and survival after lung resection for non–small cell lung cancer in patients with microscopic residual disease at the bronchial stump. Eur J Cardiothorac Surg. 1999;16:555–59.CrossRefPubMedGoogle Scholar
  7. 7.
    Ginsberg RJ, Rubinstein LV, Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1 N0 non–small cell lung cancer. Ann Thorac Surg. 1995;60:615–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Meng D, Zhou Z, Wang Y, Wang L, Lv W, Hu J. Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2016;50:597–604.CrossRefPubMedGoogle Scholar
  9. 9.
    Cao C, Gupta S, Chandrakumar D, Tian DH, Black D, Yan TD. Meta-analysis of intentional sublobar resections versus lobectomy for early stage non–small cell lung cancer. Ann Cardiothorac Surg. 2014;3:134–41.PubMedPubMedCentralGoogle Scholar
  10. 10.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352(9124):257–63.CrossRefGoogle Scholar
  11. 11.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non–small cell lung cancer. Cochrane Database Syst Rev. 2005;(2):CD002142.Google Scholar
  12. 12.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non–small cell lung cancer. Cochrane Database Syst Rev. 2000;(2):CD002142.Google Scholar
  13. 13.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol. 2015;10:148–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Mikell JL, Gillespie TW, Hall WA, et al. Postoperative radiotherapy is associated with better survival in non–small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. J Thorac Oncol. 2015;10:462–71.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.CrossRefGoogle Scholar
  17. 17.
    Eaton BR, Pugh SL, Bradley JD, et al. Institutional enrollment and survival among NSCLC patients receiving chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst. 2016;108:djw034.Google Scholar
  18. 18.
    Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18:2327–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Birkmeyer JD, Sun Y, Wong SL, Stukel TA. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777–83.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001;345:181–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Whittle J, Steinberg EP, Anderson GF, Herbert R. Use of Medicare claims data to evaluate outcomes in elderly patients undergoing lung resection for lung cancer. Chest. 1991;100:729–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Silvestri GA, Handy J, Lackland D, Corley E, Reed CE. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest. 1998;114:675–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Machtay M, Lee JH, Shrager JB, Kaiser LR, Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol. 2001;19:3912–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006.CrossRefPubMedGoogle Scholar
  25. 25.
    Wang EH, Corso CD, Park HS, et al. Association between radiation dose and outcomes with postoperative radiotherapy for N0–N1 non–small cell lung cancer. Am J Clin Oncol. In press.Google Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Todd A. Pezzi
    • 1
  • Abdallah S. R. Mohamed
    • 2
    • 3
  • Clifton D. Fuller
    • 2
  • Pierre Blanchard
    • 2
    • 4
  • Christopher Pezzi
    • 5
  • Boris Sepesi
    • 6
  • Stephen M. Hahn
    • 2
  • Daniel R. Gomez
    • 2
  • Stephen G. Chun
    • 2
  1. 1.Baylor College of MedicineHoustonUSA
  2. 2.Division of Radiation OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Department of Clinical Oncology and Nuclear MedicineAlexandria UniversityAlexandriaEgypt
  4. 4.Department of Radiation OncologyGustave Roussy Cancer CampusVillejuifFrance
  5. 5.Department of SurgeryAbington Hospital-Jefferson HealthAbingtonUSA
  6. 6.Division of Surgery, Department of Thoracic and Cardiovascular SurgeryUniversity of Texas, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations